Mid-term Business Plan 2027 Position we aspire to establish by 2033 This information is based on the "Mid-term Business Plan 2027" announced in April 2023. This information is based on the "Mid-term Business Plan 2027" announced in April 2023.

Introduction

We aim to establish ourselves as a Global Specialized Player by 2033.

With a focus on the Psychiatry & Neurology and Oncology as priority disease areas, Sumitomo Pharma Group (the “Group”) will contribute to the betterment of healthcare and fuller lives of people worldwide through diverse approaches, including pharmaceutical products, regenerative medicine/cell therapy, and non-pharmaceutical solutions. In other areas, too, the Group will leverage its assets to deliver value to patients. With this, the Group aims to establish itself as a Global Specialized Player (“GSP”) by 2033.

The basic strategy of the Mid-term Business Plan 2027 (FY2023-FY2027), which was formulated in April 2023, is to make a “qualitative transformation” of the business structure and business practices.

In the meantime, the Company will build a foothold for achieving renewed growth after the expiration of the exclusive marketing period for LATUDA® (atypical antipsychotic) in the U.S. and for establishing a position as a GSP.

Approach to 2033

Establish position as a Global Specialized Player (GSP)

We will establish a unique position globally by contributing to the betterment of healthcare and fuller lives of people worldwide through diverse approaches including pharmaceutical products, Regenerative Medicine/Cell Therapy, and non-pharmaceutical solutions, focusing on the Psychiatry & Neurology, and Oncology areas as our priority disease areas.

• • Small molecule

    

    Molecular
    design/synthesis
    based on accumulated
    experience/know-how

  • Regenerative
    medicine/cell therapy

    

    Know-how acquired by
    pioneering initiatives

  • Non-pharmaceutical
    (Frontier)

    

    To be developed
    in the
    mental
    resilience area

  • Other modalities

    

    Pursuit of optimal
    modalities

  • Psychiatry & Neurology Area

    Diverse approaches to innovate the
    conventional treatment system

    • Our core area
    • Accumulated data, experience, and know-how

  • Oncology Area

    Distinguished products to innovate
    standard treatment

    • Carefully selected R&D pipeline
    • Unique fundamentals for drug discovery

  • Other Areas

    Deliver value to patients by
    leveraging our assets

    • Women’s health issues, urological diseases, diabetes
    • Rare diseases, infectious diseases